Increased proliferation and analysis of differential gene expression in human Wharton's jelly-derived mesenchymal stromal cells under hypoxia U Nekanti, S Dastidar, P Venugopal, S Totey, M Ta International journal of biological sciences 6 (5), 499, 2010 | 228 | 2010 |
Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells SM Maffioletti, MFM Gerli, M Ragazzi, S Dastidar, S Benedetti, ... Nature protocols 10 (7), 941-958, 2015 | 107 | 2015 |
Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells S Dastidar, S Ardui, K Singh, D Majumdar, N Nair, Y Fu, D Reyon, ... Nucleic acids research 46 (16), 8275-8298, 2018 | 89 | 2018 |
Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy N Nair, MY Rincon, H Evens, S Sarcar, S Dastidar, E Samara-Kuko, ... Blood, The Journal of the American Society of Hematology 123 (20), 3195-3199, 2014 | 86 | 2014 |
Transposon-mediated gene transfer into adult and induced pluripotent stem cells E Belay, S Dastidar, T VandenDriessche, M KL Chuah Current gene therapy 11 (5), 406-413, 2011 | 41 | 2011 |
Therapeutic approaches for dominant muscle diseases: highlight on myotonic dystrophy A F Klein, S Dastidar, D Furling, M K Chuah Current gene therapy 15 (4), 329-337, 2015 | 39 | 2015 |
piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts M Loperfido, S Jarmin, S Dastidar, M Di Matteo, I Perini, M Moore, N Nair, ... Nucleic acids research 44 (2), 744-760, 2016 | 35 | 2016 |
Advanced models of human skeletal muscle differentiation, development and disease: Three-dimensional cultures, organoids and beyond S Jalal, S Dastidar, FS Tedesco Current opinion in cell biology 73, 92-104, 2021 | 34 | 2021 |
3D human induced pluripotent stem cell–derived bioengineered skeletal muscles for tissue, disease and therapy modeling L Pinton, M Khedr, VM Lionello, S Sarcar, SM Maffioletti, S Dastidar, ... Nature Protocols 18 (4), 1337-1376, 2023 | 17 | 2023 |
Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes S Dastidar, D Majumdar, J Tipanee, K Singh, AF Klein, D Furling, ... Molecular Therapy 30 (1), 75-91, 2022 | 13 | 2022 |
Generation of hepatocyte-and endocrine pancreatic-like cells from human induced endodermal progenitor cells R Sambathkumar, R Akkerman, S Dastidar, P Roelandt, M Kumar, M Bajaj, ... Plos one 13 (5), e0197046, 2018 | 4 | 2018 |
Gene Therapy and Gene Editing for Myotonic Dystrophy M Chuah, YC Chai, S Dastidar, T VandenDriessche Muscle Gene Therapy, 525-548, 2019 | 3 | 2019 |
Computationally designed liver-specific transcriptional cis-regulatory modules and hyper-functional factor IX improve liver-targeted gene therapy for hemophilia B. NNS Nair, MY Rincon, H Evens, S Sarcar, S Dastidar, E Samara, ... Blood 123 (20), 3195-3199, 2014 | 2 | 2014 |
CRISPR/Cas9-mediated editing for dominant genetic disorders: efficient excision of trinucleotide repeat expansion in myotonic dystrophy S Dastidar, S Ardui, K Singh, N Nair, Y Fu, D Reyon, E Samara, MFM Gerli, ... Human Gene Therapy 28 (12), A7-A7, 2017 | 1 | 2017 |
Evaluating the therapeutic potential of CRISPR/Cas9 based gene editing in a newly developed inducible multi-systemic myotonic dystrophy mouse model D Majumdar, S Dastidar, M Janssens, M Chuah, T VandenDriessche Human Gene Therapy 35 (3-4), A44-A45, 2024 | | 2024 |
CRISPR-Cas9 mediated endogenous utrophin upregulation improves Duchenne Muscular Dystrophy S Guiraud, S Dastidar, F Mazed, F Amor, M Ralu, A de Cian, I Richard, ... bioRxiv, 2023.04. 18.536394, 2023 | | 2023 |
Modelling multi-tissue involvement in Duchenne muscular dystrophy using advanced in vitro models of human striated muscle T Torun, S Dastidar, FS Tedesco HUMAN GENE THERAPY 33 (23-24), A206-A207, 2022 | | 2022 |
Developing next-generation neuromuscular therapeutics using quasi vivo 3D human skeletal muscles S Dastidar, S Guiraud, S Sarcar, M Khedr, L Pinton, E Negroni, ... HUMAN GENE THERAPY 33 (23-24), A120-A120, 2022 | | 2022 |
Development of a utrophin modulation CRISPR-Cas9 strategy for Duchenne Muscular Dystrophy S Guiraud, C Fauveau, F Mazzed, S Dastidar, F Amor, G Ronzitti, ... HUMAN GENE THERAPY 32 (19-20), A125-A125, 2021 | | 2021 |
Genome Editing for Myotonic Dystrophy Type 1. S Dastidar | | 2019 |